EORTC 24051: Unexpected side effects in a phase i study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma

Radiotherapy and Oncology

Volumn 105, Issue 2, 2012, Pages 238-240

  Lalami, Yassine ^a   Specenier, Pol M ^b   Awada, Ahmad ^a   Lacombe, Denis ^c   Liberatoscioli, Cecilia ^c   Fortpied, Catherine ^c   El Hariry, Iman ^d   Bogaerts, Jan ^c   Andry, Guy ^a   Langendijk, J A ^e   Vermorken, Jan B ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c EORTC DATA CENTER   (Belgium)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemoradiation; Head and neck cancer; Induction chemotherapy; Lapatinib

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; LAPATINIB;

ADVANCED CANCER; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYDRATION; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; STOMATITIS; TREATMENT RESPONSE; URTICARIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; INDUCTION CHEMOTHERAPY; LARYNGEAL NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TAXOIDS;

EID: 84871330978     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.08.006     Document Type: Article

References (20)

1. J. Bernier Current state-of-the-art for concurrent chemoradiation Semin Radiat Oncol 19 2009 3 10
2. A. Forastiere, B. Berkey, and M. Maor Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone: intergroup trial R91-11 N Engl J Med 349 2003 2091 2098
3. T.G. Wendt, G.G. Grabenbauer, and C.M. Rodel Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study J Clin Oncol 16 1998 1318 1324
4. M. Machtay, J. Moughan, and A. Trotti Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 2008 3582 3589
5. E. Vokes, R. Weichselbaum, and S. Lippman Head and neck cancer N Engl J Med 328 1993 184 194
6. J.P. Pignon, A. Le Maitre, and E. Maillard Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
7. M.R. Posner, D.M. Herschock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715
8. M.R. Posner, C.M. Norris, and L.J. Wirth Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX324: survival, surgery, and organ preservation Ann Oncol 20 2009 921 927
9. J.B. Vermorken, E. Remenaer, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704
10. Y. Pointreau, P. Garaud, and S. Chapet Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation J Natl Cancer Inst 101 2009 498 506
11. P. Blanchard, B. Baujat, and V. Holostenco Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site Radiother Oncol 98 2011 S6 [Abstract #4]
12. J. Santini, J.L. Formento, and M. Francoual Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas Head Neck 13 1991 132 139
13. J.R. Grandis, M.F. Melhem, and E.L. Barnes Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 78 1996 1284 1292
14. J.R. Grandis, M.F. Melhem, and W.E. Gooding Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824 832
15. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
16. D.W. Rusnak, K. Lackey, and K. Affleck The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 2001 85 94
17. M. Versola, H.A. Burris, and S. Jones Clinical activity of GW572016 in EGF10003 in patients with solid tumors J Clin Oncol 2004 23 [Abstract 22]
18. J.M. Del Campo, R. Hitt, and P. Sebastian Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naïve patients with locally advanced squamous cell carcinoma of the head and neck Br J Cancer 105 2011 618 627
19. P.M. LoRusso, S.F. Jones, and K.M. Koch Phase I pharmacokinetics study of lapatinib and docetaxel in patients with advanced cancer J Clin Oncol 26 2008 3051 3056
20. K.J. Harrington, A. El-Hariry, and C.S. Holford Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1100 1107